Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Friday 30th October 2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ended ....

AMERISE BIOSCIENCES LIMITED CIN: L29199GJ1984PLC007195 (Formerly Known as AMRADEEP INDUSTRIES LIMITED) Date: 30.10.2026 Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Dear Sir / Madam, Scrip Code: 531681 Security ID: AMERISE Subject: Outcome of Board Meeting held on 30th October 2026. Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Friday 30th October 2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2026. The board meeting commented at 03:45 PM and concluded at 04:15 PM Please take the above intimation in your records. Thanking You, Yours Faithfully, For, Amerise Biosciences Limited ALBERT HINES Whole-time Director DIN: 10742692 REG. OFFICE: 24, LAXMI CHAMBERS, NAVJEEVAN PRESS ROAD, OPP. OLD GUJARAT HIGH CORT, AHMEDABAD-380014. E Mail: amradeepindustries@gmail.com Amerise Biosciences Limited CIN:-L29199GJ1984PLC007195 Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014 Email:- amradeepindustries@gmail.com Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2026 Quarter Ended Six Months Ended (Rs. In lacs) Year Ended 31 Sl no. Particulars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 Mar 2026 (Refer Notes Below) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 INCOME (a) Revenue From Operation - - - - - - (b) Other Income - - 6.75 - 13.11 25.52 Total Income from Operations (Net) - - 6.75 - 13.11 25.52 2 EXPENSES - (a) Cost of material consumed - - - - - - (b) Changes in inventories of finished goods, work-in-progress, - - - - - - and stock-in-trade (c) Employee benefit expense 0.82 0.94 1.80 1.76 4.12 7 .37 (d) Finance Costs - - - - - - (e) Depreciation and amortization expense - - - - - (f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing 4.94 7.21 9.18 12.15 14.03 1 6.09 operations to be shown separately) Total Expenses 5.76 8.14 10.98 13.91 18.15 2 3.46 3 Profit / (Loss) from operations before exceptional items ( 5.76) (8.14) ( 4.23) ( 13.91) ( 5.04) 2 .06 Tax (1-2) 4 Exceptional Items - - - - - - 5 Profit / (Loss) before Tax (3 ± 4) ( 5.76) (8.14) ( 4.23) ( 13.91) ( 5.04) 2 .06 6 Tax Expense - - - - - 0 .45 7 Net Profit / (Loss) after Tax (5 - 6) ( 5.76) (8.14) ( 4.23) ( 13.91) ( 5.04) 1 .61 8 Other Comprehensive Income (net of tax ) - - - - - - 9 Total Comprehensive Income for the period (7 ± 8) ( 5.76) (8.14) ( 4.23) ( 13.91) ( 5.04) 1 .61 10 Paid-up equity share capital (Face Value of Rs.1/- each) 660.69 660.69 660.69 660.69 660.69 6 60.69 11 Other Equity - - - - - ( 121.10) 12 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic ( 0.01) (0.01) ( 0.01) ( 0.02) ( 0.01) 0 .00 (b) Diluted ( 0.01) (0.01) ( 0.01) ( 0.02) ( 0.01) 0 .00 Amerise Biosciences Limited CIN:-L29199GJ1984PLC007195 Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014 Email:- amradeepindustries@gmail.com (Rs. in Lakhs) Standalone Statement of Assets and Liabilities As at 30th September, 2026 As at 31st March, 2026 Particulars Un-Audited Audited A ASSETS 1 Non-current assets Property, plant and equipment - - Capital work-in-progress - - Other intangible assets - - Investments in subsidiaries, associates and joint ventures - - Financial assets Investments 376.75 376.97 Loans 300.20 304.03 Other financial assets - - Income Tax assets (net) - - Deferred tax assets (net) - - Other non-current assets - - Sub-total - Non-Current Assets 676.95 681.00 2 Current assets Inventories - - Financial assets - Investments - - Trade receivables - - Cash and cash equivalents 2.46 59.19 Bank balances other than Cash and Cash equivalents above - Loans, Current - - Other financial assets - - Other current assets 2.00 2.00 Assets classified as held for sale - - Sub-total - Current Assets 4.46 61.19 TOTAL - ASSETS 681.41 742.19 B EQUITY AND LIABILITIES 1 Equity Equity Share capital 660.69 660.69 Other equity ( 135.01) (121.10) Sub-total - Shareholders' funds 525.68 539.59 2 LIABILITIES Non-current liabilities Financial liabilities Borrowings, non-Current - - Provisions - - Income tax liabilities (net) - - Other non-current liabilities - - Sub-total - Non-current liabilities - - 3 Current liabilities Financial liabilities Borrowings, Current 3.00 - Trade payables, Current - - Other financial liabilities 152.00 202.00 Other current liabilities 0.27 0.15 Provisions 0.45 0.45 Current tax liabilities (net) - - Sub-total - Current liabilities 155.72 202.60 TOTAL - EQUITY AND LIABILITIES 681.41 742.19 Amerise Biosciences Limited CIN:-L29199GJ1984PLC007195 Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014 Email:- amradeepindustries@gmail.com Notes: 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 30, 2026. 2 The Statutory Auditors have carried out a limited review of the above financial result. 3 Company has only one segment and hence no separate segment result has been given. 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary. 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Amerise Biosciences Limited Place : AAhhmmededbaabdad Albert Hines Date : 30th October, 2026 Wholetime Director Amerise Biosciences Limited CIN:-L29199GJ1984PLC007195 Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014 Email:- amradeepindustries@gmail.com (Rs. in Lakhs, unless otherwise stated) 30.09.2026 30.09.2025 Particulars Rupees Rupees A. CASH FLOW FROM OPERATING ACTIVITIES: Profit before tax - 13.91 - 5.04 Adjustment For : Share of (profit)/loss from investment in partnership firm - - Depreciation/amortization on continuing operation - - Interest expenses - - Operating profit before working capital changes - 13.91 - 5.04 Movement in Working Capital : Increase/(decrease) in Inventory - - Increase/(decrease) in Trade receivables - - Increase/(decrease) in Short Term Loan & Advances - - Increase/(decrease) in Current Liabilities - 4 9.88 - 1 .98 Increase/(decrease) in Trade Payable - - Increase/(decrease) in Other Current Assets 0.00 - Direct taxes paid (net of refunds) - Net Cash Flow from Operating Activities(A) - 6 3.78 - 7.02 B. CASH FLOW FROM INVESTING ACTIVITIES Investments /withdrawl in Partnership Firm 0.22 - 138.87 Purchase / Sale of Fixed Assets - - Increase/(decrease) in Long Term Loan & Advances 3.83 146.05 Net Cash Flow from Invesing Activities(B) 4.05 7.18 C. CASH FLOW FROM FINANCING ACTIVITIES Proceed (Repayment) from long term borrowing - - Proceed (Repayment) from short term borrowing 3.00 - Proceed from Preferenital Warrants - - Net Cash Flow from Financing Activities(C) 3.00 - Net increase/(decrease) in cash & cash equivalents(A+B+C) - 5 6.73 0 .16 Cash and Cash equivalents (Opening Balance) 5 9.19 2 .22 Cash and Cash equivalents (Closing Balance) 2.46 2.38 Previous year figure have been regrouped/ reclassified wherever necessary As per our report of even date For, Bipin & Co. For and on Behalf of the Board Chartered Accountants CA Amit Shah Partner Albert Hines M. No.: 126337 Wholetime Director Place: Vadodara Place: Ahmedabad Date : 30th October, 2026 Date : 30th October, 2026 BIPIN & Co. CA CA. TEJAS [Showing first 8,000 characters — download PDF for full document]